IN2012DN06587A - - Google Patents

Info

Publication number
IN2012DN06587A
IN2012DN06587A IN6587DEN2012A IN2012DN06587A IN 2012DN06587 A IN2012DN06587 A IN 2012DN06587A IN 6587DEN2012 A IN6587DEN2012 A IN 6587DEN2012A IN 2012DN06587 A IN2012DN06587 A IN 2012DN06587A
Authority
IN
India
Prior art keywords
prophylaxis
compositions
treatment
equal
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Jatin Patel
Charles Frost
Jingpin Jia
Varapu Chandra Vema
Original Assignee
Bristol Myers Squibb Co
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06587(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Pfizer filed Critical Bristol Myers Squibb Co
Publication of IN2012DN06587A publication Critical patent/IN2012DN06587A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
IN6587DEN2012 2010-02-25 2011-02-24 IN2012DN06587A (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25
PCT/US2011/025994 WO2011106478A2 (en) 2010-02-25 2011-02-24 Apixaban formulations

Publications (1)

Publication Number Publication Date
IN2012DN06587A true IN2012DN06587A (it) 2015-10-23

Family

ID=43901603

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6587DEN2012 IN2012DN06587A (it) 2010-02-25 2011-02-24

Country Status (31)

Country Link
US (5) US9326945B2 (it)
EP (7) EP3251660B1 (it)
JP (4) JP5846647B2 (it)
KR (4) KR101796300B1 (it)
CN (3) CN109602713A (it)
AU (1) AU2011220775B2 (it)
BR (1) BR112012021337A8 (it)
CA (1) CA2791171C (it)
CO (1) CO6640207A2 (it)
CY (5) CY1117434T1 (it)
DK (5) DK2538925T3 (it)
ES (5) ES2757603T3 (it)
HK (5) HK1224216A1 (it)
HR (5) HRP20160179T1 (it)
HU (4) HUE047140T2 (it)
IL (3) IL309564A (it)
IN (1) IN2012DN06587A (it)
LT (4) LT3257500T (it)
MX (3) MX353145B (it)
NZ (1) NZ601738A (it)
PE (3) PE20130378A1 (it)
PL (5) PL2538925T3 (it)
PT (5) PT3257500T (it)
RS (5) RS58699B1 (it)
RU (1) RU2685724C2 (it)
SG (2) SG182750A1 (it)
SI (5) SI3017811T1 (it)
SM (1) SMT201600049B (it)
TR (1) TR201903195T4 (it)
WO (1) WO2011106478A2 (it)
ZA (1) ZA201205807B (it)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
US20150018386A1 (en) * 2012-03-06 2015-01-15 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
CA2873949A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
SG10201702048VA (en) * 2012-09-26 2017-04-27 Bristol Myers Squibb Holdings Ireland Apixaban liquid formulations
CN102908324A (zh) * 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
WO2014203275A2 (en) * 2013-06-18 2014-12-24 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
CN104316637B (zh) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 高效液相色谱法测定阿哌沙班清洗残留量
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
EP3236965A1 (en) * 2015-05-08 2017-11-01 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法
CN108472261B (zh) * 2016-01-12 2021-12-03 广东东阳光药业有限公司 阿哌沙班固体组合物及其制备方法
EP3195860A1 (de) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
CN109069502B (zh) * 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
CN106420651B (zh) * 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
KR102470151B1 (ko) 2017-11-27 2022-11-25 미쯔비시 케미컬 주식회사 고무 함유 그래프트 중합체, 고무 함유 그래프트 중합체 함유 수지 조성물 및 그의 성형체
KR20190075566A (ko) 2017-12-21 2019-07-01 전자부품연구원 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
CA3097176A1 (en) 2018-04-16 2019-10-24 Bristol-Myers Squibb Company Apixaban formulations
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
US20210299059A1 (en) 2018-08-14 2021-09-30 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (zh) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 一种吡唑并-吡啶酮化合物晶型d
CN109464415B (zh) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
CN111214442B (zh) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
EP4251155A1 (en) * 2020-11-27 2023-10-04 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
TR202100250A2 (tr) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren fi̇lm kapli tablet
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
DK1140941T3 (da) 1998-12-23 2005-02-14 Bristol Myers Squibb Pharma Co Nitrogenholdige heterobicykliske forbindelser som faktor Xa-inhibitorer
CA2726702A1 (en) 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
WO2007053904A1 (en) 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
CA2662542A1 (en) 2006-09-12 2008-03-20 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
PT2146705E (pt) * 2007-05-02 2014-05-23 Portola Pharm Inc Terapia de combinação com um composto que atua como inibidor do recetor de adp de plaquetas
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009135946A1 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
KR20110043655A (ko) 2008-07-11 2011-04-27 바스프 에스이 모폴로지 변경제로서의 양친매성 단백질
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2012101214A (ru) * 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
AU2011225810B2 (en) * 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension

Also Published As

Publication number Publication date
HUE047139T2 (hu) 2020-04-28
SI3017811T1 (sl) 2019-04-30
PL2538925T3 (pl) 2016-06-30
PT3246021T (pt) 2020-02-21
JP2013521226A (ja) 2013-06-10
RU2012140690A (ru) 2014-03-27
PE20130378A1 (es) 2013-03-30
TR201903195T4 (tr) 2019-03-21
PL3251660T3 (pl) 2020-02-28
HRP20192069T1 (hr) 2020-02-07
NZ601738A (en) 2014-02-28
HK1243946A1 (zh) 2018-07-27
CA2791171A1 (en) 2011-09-01
HRP20160179T1 (hr) 2016-04-08
HK1243945B (zh) 2020-06-19
JP2017039768A (ja) 2017-02-23
ES2714363T3 (es) 2019-05-28
KR101796300B1 (ko) 2017-11-10
WO2011106478A2 (en) 2011-09-01
LT3257500T (lt) 2019-12-10
DK2538925T3 (en) 2016-03-14
HRP20192064T1 (hr) 2020-02-21
EP3251660B1 (en) 2019-10-16
US20200375968A1 (en) 2020-12-03
RS54559B1 (en) 2016-06-30
ES2767848T3 (es) 2020-06-18
CY1121597T1 (el) 2020-05-29
DK3257500T3 (da) 2019-11-25
SG182750A1 (en) 2012-08-30
EP3246021A1 (en) 2017-11-22
RS59576B1 (sr) 2019-12-31
EP2538925A2 (en) 2013-01-02
JP6192078B2 (ja) 2017-09-06
SI3251660T1 (sl) 2019-12-31
HUE027168T2 (en) 2016-10-28
HRP20190430T1 (hr) 2019-05-17
RU2685724C2 (ru) 2019-04-23
CY1117434T1 (el) 2017-04-26
HK1180248A1 (zh) 2013-10-18
DK3017811T3 (en) 2019-04-01
HRP20190430T8 (hr) 2019-06-14
JP2016065086A (ja) 2016-04-28
EP3257500B1 (en) 2019-10-16
CN109602716A (zh) 2019-04-12
KR20130009753A (ko) 2013-01-23
EP2538925B1 (en) 2015-12-16
CY1122384T1 (el) 2021-01-27
IL221064A0 (en) 2012-09-24
MX353145B (es) 2017-12-20
SMT201600049B (it) 2016-04-29
ES2757603T3 (es) 2020-04-29
KR20230149861A (ko) 2023-10-27
PT3257500T (pt) 2019-11-26
CA2791171C (en) 2017-08-29
HK1243947B (zh) 2020-06-19
US20160243101A1 (en) 2016-08-25
IL251991A0 (en) 2017-06-29
SG10201501349VA (en) 2015-04-29
ES2562279T3 (es) 2016-03-03
US20170202825A1 (en) 2017-07-20
PE20160042A1 (es) 2016-01-28
JP2017226679A (ja) 2017-12-28
BR112012021337A8 (pt) 2016-11-29
ES2758031T3 (es) 2020-05-04
ZA201205807B (en) 2016-01-27
SI3257500T1 (sl) 2019-12-31
PL3246021T3 (pl) 2020-04-30
PT3017811T (pt) 2019-03-21
RS59593B1 (sr) 2020-01-31
KR20170126016A (ko) 2017-11-15
JP6033945B2 (ja) 2016-11-30
EP3257500A1 (en) 2017-12-20
KR20210124532A (ko) 2021-10-14
HUE047140T2 (hu) 2020-04-28
LT3017811T (lt) 2019-02-25
JP6577980B2 (ja) 2019-09-18
DK3251660T3 (da) 2019-11-25
CO6640207A2 (es) 2013-03-22
PL3017811T3 (pl) 2019-06-28
AU2011220775A1 (en) 2012-09-13
EP3643301A1 (en) 2020-04-29
BR112012021337A2 (pt) 2016-10-25
SI3246021T1 (sl) 2020-03-31
AU2011220775B2 (en) 2015-09-24
SI2538925T1 (sl) 2016-04-29
HRP20200046T1 (hr) 2020-03-20
CY1122382T1 (el) 2021-01-27
CN102770126A (zh) 2012-11-07
EP3017811B1 (en) 2018-12-05
HUE043932T2 (hu) 2019-09-30
HK1224216A1 (zh) 2017-08-18
CN109602713A (zh) 2019-04-12
WO2011106478A3 (en) 2012-04-12
MX364938B (es) 2019-05-15
US20170202824A1 (en) 2017-07-20
PT2538925E (pt) 2016-03-18
CY1122529T1 (el) 2021-01-27
IL309564A (en) 2024-02-01
DK3246021T3 (da) 2020-02-03
PE20210468A1 (es) 2021-03-08
PL3257500T3 (pl) 2020-03-31
EP3017811A1 (en) 2016-05-11
US20130045245A1 (en) 2013-02-21
EP3246021B1 (en) 2019-11-13
LT3246021T (lt) 2020-02-10
LT3251660T (lt) 2019-12-10
RS58699B1 (sr) 2019-06-28
JP5846647B2 (ja) 2016-01-20
RS59810B1 (sr) 2020-02-28
EP3662899A1 (en) 2020-06-10
MX2012009244A (es) 2012-08-23
ES2758031T8 (es) 2020-08-05
PT3251660T (pt) 2019-12-02
EP3251660A1 (en) 2017-12-06
US9326945B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
IN2012DN06587A (it)
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
CA2818187C (en) Bromodomain inhibitors and uses thereof
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MX2013008902A (es) Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
MX2013010511A (es) Inhibidores triciclicos de girasa.
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2013002660A (es) Heteroarilmetilamidas.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010005714A (es) Compuestos de piridina.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
EP2605289A4 (en) ETCHING-TEXTURING AGENT COMPOSITION FOR CRYSTALLINE SILICON PLATEBOARD AND ETCHING-TEXTURING METHOD (1)
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
EP2604724A4 (en) TEXTURE AGENT FOR CRYSTALLINE SILICON WAFERS AND TEXTURE METAL PROCESSES (2)
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
WO2011139253A3 (en) Pharmaceutical compositions comprising ceftibuten
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
WO2014015153A3 (en) Treating ewing's sarcoma and ews-fli1 related disorders
WO2012023145A3 (en) Prasugrel hydrochloride crystalline particles
MX2013007504A (es) Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina.
WO2012065100A3 (en) Cxcr4 as a susceptibility locus in juvenile idiopathic arthritis (jia) and methods of use thereof for the treatment and diagnosis of the same
WO2011151395A3 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
TN2010000391A1 (en) Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
JOP20120346B1 (ar) مركبات لعلاج ومنع الإلتصاق، وتركيبات صيدلية متعلقة بالمركب وطرق لمنع وعلاج الإلتصاقات